Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

December 31, 2003

Conditions
HIV
Interventions
DRUG

Maraviroc (UK-427,857)

150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)

DRUG

Maraviroc (UK-427,857)

100 mg oral tablet once daily while fasted on Days 1-10

DRUG

Maraviroc (UK-427,857)

300 mg oral tablet once daily while fasted on Days 1-10

DRUG

Maraviroc (UK-427,857)

150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)

OTHER

Placebo

Matching placebo oral tablet on Days 1-10 (fed and fasted)

Trial Locations (7)

20099

Pfizer Investigational Site, Hamburg

50931

Pfizer Investigational Site, Cologne

60596

Pfizer Investigational Site, Frankfurt

35294-2050

Pfizer Investigational Site, Birmingham

02215

Pfizer Investigational Site, Boston

NW3 2QG

Pfizer Investigational Site, London

SW10 9NH

Pfizer Investigational Site, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT00634959 - Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus | Biotech Hunter | Biotech Hunter